Menu
 

Search abstracts


Real-world experience with idarucizumab for dabigatran reversal in a third-level hospital

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: DOMINGUEZ BRAHONA, Ana (Hospital Virgen de la Salud, Pharmacy)
  • Co-author(s): Ana Dominguez Barahona
    Cristina Blázquez Romero
    Helena Quirós Ambel
    Ana García Sacristán
    Silvia Gonzalez Suarez
    Ana Rosa Rubio Salvador
    Nuria Labrador Andújar
    Paloma Moya Gomez
  • Abstract:

    Background

    Idarucizumab has been approved for use when reversal of the anticoagulant effects of dabigatran is needed for urgent procedures or in patients with life-threatening bleeding.

    Methods

    Observational, descriptive, retrospective (April 2017-April 2018) and longitudinal study of patients treated with idarucizumab in a general hospital of 650

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses